Development of a Saccharomyces boulardii probiotic yeast strain expressing interleukin 1 receptor suppressor nanobodies for the treatment of inflammatory bowel diseases
6th INTERNATIONAL MOLECULAR IMMUNOLOGY & IMMUNOGENETICS CONGRESS (MIMIC-VI), İstanbul, Türkiye, 28 - 30 Nisan 2025, (Yayınlanmadı)
- Yayın Türü: Bildiri / Yayınlanmadı
- Basıldığı Şehir: İstanbul
- Basıldığı Ülke: Türkiye
- Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet
Özet
Saccharomyces boulardii, a non-pathogenic yeast isolated from lychee fruit, is a commercially available anti-inflammatory probiotic. S.boulardii has been extensively studied for its ability to support gastrointestinal health and immune regulation. This project aims to develop a novel agent that specifically inhibits the interleukin-1 receptor using S.boulardii as a host for nanobody expression. Nanobodies or VHH proteins are cameloid derived antibodies which have therapeutic applications. Their small size and high affinity confer some advantages over antibodies such as effectively penetrating tumors. Nanobodies targeting the IL1 receptor pathway involved in inflammatory and autoimmune diseases have been developed. The diseases that are characterized by the dysregulation of the IL-1 pathway, such as Familial Mediterranean Fever and Behcet's Disease, can be treated by therapeutics targeting this pathway, such as Anakinra and Canakinumab. But these treatment modes have limitations such as reduced efficacy over time and the requirement for frequent administration. Within the project, a cDNA encoding a nanobody that we discovered in our previous studies, which specifically targets the IL-1 receptor and inhibits the IL-1 signaling pathway, will be expressed on the surface of S.Boulardii. A new therapeutic strategy will be developed by providing functional nanobody expression in S.Boulardii.